Smartleaf Asset Management
IPSC icon

Smartleaf Asset Management’s Century Therapeutics IPSC Stock Holding History

Smartleaf Asset Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2 Hold
1
– – ﹤0.01% 3618
2026
Q2 		$2 Hold
1
– – ﹤0.01% 3459
2026
Q1 		$2 Hold
1
– – ﹤0.01% 3502
2025
Q4 		$1 Buy
+1
New +$1 ﹤0.01% 3488
2024
Q4 		– Sell
-1,609
Closed -$2.59K – 2964
2024
Q3 		$2.59K Buy
+1,609
New +$3.15K ﹤0.01% 2395

Other funds holding IPSC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Smartleaf Asset Management's IPSC Position: Q3 2026 in Review

Smartleaf Asset Management held its Century Therapeutics (IPSC) position steady in Q3 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #3618.

Smartleaf Asset Management first reported a position in IPSC in Q3 2024 and has held it in 5 quarters since. The position peaked at $2.59K in Q3 2024. 33 funds tracked by Wall St. Rank hold IPSC as of Q3 2026.

  • Smartleaf Asset Management held 1 share of Century Therapeutics worth $2 as of Q3 2026.
  • Smartleaf Asset Management left its Century Therapeutics share count unchanged in Q3 2026.
  • Century Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #3618 holding.
  • Smartleaf Asset Management first reported a position in Century Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Smartleaf Asset Management's Century Therapeutics position peaked at $2.59K in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.